IFC Advisors’s iShares Biotechnology ETF IBB Stock Holding History

IFC Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$288K	Hold	1,513	–	–	0.04%	145
2026 Q1	$256K	Hold	1,513	–	–	0.04%	133
2025 Q4	$255K	Hold	1,513	–	–	0.04%	153
2025 Q3	$218K	Buy	+1,513	New	+$207K	0.04%	163
2025 Q1	–	Sell	-1,513	Closed	-$200K	–	167
2024 Q4	$200K	Buy	+1,513	New	+$213K	0.04%	141

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

IFC Advisors's IBB Position: Q2 2026 in Review

IFC Advisors held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 1,513 shares worth $288K. The position accounts for 0.04% of the portfolio, ranked #145.

IFC Advisors first reported a position in IBB in Q4 2024 and has held it in 5 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

IFC Advisors held 1,513 shares of iShares Biotechnology ETF worth $288K as of Q2 2026.
IFC Advisors left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.04% of IFC Advisors's portfolio in Q2 2026, its #145 holding.
IFC Advisors first reported a position in iShares Biotechnology ETF in Q4 2024 and has held it in 5 quarters since.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on IFC Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.